Paper · 42360909
FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression.
Zhang W and 12 others. Blood, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression. Papers, record 42360909. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42360909
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Fibroblast Growth Factors | Major topic |
| Fibroblasts | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Disease Progression | |
| Receptor, Fibroblast Growth Factor, Type 3 | |
| Signal Transduction | |
| Tumor Microenvironment | |
| TOR Serine-Threonine Kinases | |
| Interleukin-6 |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 42,821,300 | Systems reboot: a niche-based approach to AML. | https://conductscience.org/library/papers/42821300 |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30,082,912 | FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. | Oncogene | 2019 | https://conductscience.org/library/papers/30082912 | PubMed |
| 2 | 38,228,679 | Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche. | Leukemia | 2024 | https://conductscience.org/library/papers/38228679 | PubMed |
| 3 | 36,574,771 | Decoding m6A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance. | Cell Stem Cell | 2023 | https://conductscience.org/library/papers/36574771 | PubMed |
| 4 | 39,480,488 | Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels. | J Clin Invest | 2024 | https://conductscience.org/library/papers/39480488 | PubMed |
| 5 | 40,663,784 | The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF-κB signaling. | Blood | 2025 | https://conductscience.org/library/papers/40663784 | PubMed |
| 6 | 37,768,887 | FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation. | Cancer Res | 2023 | https://conductscience.org/library/papers/37768887 | PubMed |
| 7 | 37,001,042 | TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice. | Blood | 2023 | https://conductscience.org/library/papers/37001042 | PubMed |
| 8 | 40,796,662 | A STUB1-CHIC2 complex inhibits CD8+ T cells to restrain tumor immunity. | Nat Immunol | 2025 | https://conductscience.org/library/papers/40796662 | PubMed |
| 9 | 36,550,214 | Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling. | Leukemia | 2023 | https://conductscience.org/library/papers/36550214 | PubMed |
| 10 | 29,563,517 | Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. | Blood Cancer J | 2018 | https://conductscience.org/library/papers/29563517 | PubMed |
1 to 10 of 59
See all 59 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| FGF18 | 8,817 | PubTator's text mining | https://conductscience.org/library/genes/8817 | NCBI Gene |
| FGFR3 | 2,261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| IL6 | 3,569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| MTOR | 2,475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PDCD1 | 5,133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| STAT3 | 6,774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42360909
GET https://conductscience.org/api/papers/v1/42360909/references?page=2